Publications

2019

• Medo M, Aebersold DM, Medová M. ProtRank: Bypassing the imputation of missing values in differential expression analysis of proteomics data. BMC Bioinformatics. 2019 Nov 9;20(1):563. doi: 10.1186/s12859-019-3144-3.
• Muñoz-Maldonado C, Zimmer Y, Medová M. A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Front Oncol. 2019 Oct 18;9:1088. doi: 10.3389/fonc.2019.01088. PMID: 31681616; PMCID: PMC6813200.
• Gavini J, Dommann N, Jakob MO, Keogh A, Bouchez LC, Karkampouna S, Julio MK, Medova M, Zimmer Y, Schläfli AM, Tschan MP, Candinas D, Stroka D, Banz V. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis. 2019 Oct 3;10(10):749. doi: 10.1038/s41419-019-1989-z. PMID: 31582741; PMCID: PMC6776510.
• Poliaková M, Felser A, Pierzchala K, Nuoffer JM, Aebersold DM, Zimmer Y, Zamboni N, Medová M. Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models. FEBS J. 2019 Jul;286(14):2692-2710. doi: 10.1111/febs.14852. Epub 2019 May 11. PMID: 30993872.
• Orlando E, Aebersold DM, Medová M, Zimmer Y. Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer Lett. 2019 Feb 28;443:189-202. doi: 10.1016/j.canlet.2018.12.001. Epub 2018 Dec 11. PMID: 30550851.

2020

• Nisa L, Francica P, Giger R, Medo M, Elicin O, Friese-Hamim M, Wilm C, Stroh C, Bojaxhiu B, Quintin A, Caversaccio MD, Dettmer MS, Buchwalder M, Brodie TM, Aebersold DM, Zimmer Y, Carey TE, Medová M. Targeting the MET receptor tyrosine kinase as a strategy for radiosensitization in locoregionally advanced head and neck squamous cell carcinoma. Mol Cancer Ther. 2020 Feb;19(2):614-626. doi: 10.1158/1535-7163.MCT-18-1274. Epub 2019 Nov 19.
• Bensimon A, Koch JP, Francica P, Roth SM, Riedo R, Glück AA, Orlando E, Blaukat A, Aebersold DM, Zimmer Y, Aebersold R*, Medová M*. Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Mol Oncol. 2020 Jun;14(6):1185-1206. doi: 10.1002/1878-0261.12696. Epub 2020 May 13. (* - shared senior authorship)
• Medová M, Medo M, Hovhannisyan L, Muñoz-Maldonado C, Aebersold DM, Zimmer Y. DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. Pharmacol Ther. 2020 Nov;215:107617. doi: 10.1016/j.pharmthera.2020.107617. Epub 2020 Jun 28.
• Zimmer Y, Reinhardt HC, Medová M. Editorial: Exploiting DNA damage response in the era of precision oncology. Front Oncol. 2020 Oct 15;10:611127. doi: 10.3389/fonc.2020.611127. eCollection 2020.
• Koch JP, Aebersold DM, Zimmer Y, Medová M. MET targeting: time for a rematch. Oncogene. 2020 Apr;39(14):2845-2862. doi: 10.1038/s41388-020-1193-8. Epub 2020 Feb 7.
• Dommann N, Sánchez-Taltavull D, Eggs L, Birrer F, Brodie T, Salm L, Baier FA, Medová M, Humbert M, Tschan MP, Beldi G, Candinas D, Stroka D. The LIM Protein Ajuba Augments Tumor Metastasis in Colon Cancer. Cancers (Basel). 2020 Jul 15;12(7):1913. doi: 10.3390/cancers12071913. PMID: 32679899; PMCID: PMC7409172.

2021

• Melin N, Sánchez-Taltavull D, Fahrner R, Keogh A, Dosch M, Büchi I, Zimmer Y, Medová M, Beldi G, Aebersold DM, Candinas D, Stroka D. Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury. Cell Death Dis. 2021 Apr 6;12(4):366. doi: 10.1038/s41419-021-03654-3. PMID: 33824326; PMCID: PMC8024273.
• Bosch-Guiteras N, Uroda T, Guillen-Ramirez HA, Riedo R, Gazdhar A, Esposito R, Pulido-Quetglas C, Zimmer Y, Medová M, Johnson R. Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs. Genome Res. 2021 Mar;31(3):461-471. doi: 10.1101/gr.265736.120. Epub 2021 Feb 11. PMID: 33574136; PMCID: PMC7919447.

2022

• Orlando E, Medo M, Bensimon A, Quintin A, Riedo R, Roth SM, Riether C, Marti TM, Aebersold DM, Medová M, Aebersold R, Zimmer Y. An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cell Mol Life Sci. 2022 Dec 10;80(1):6. doi: 10.1007/s00018-022-04634-2.
• Schanne DH, Koch A, Elicin O, Giger R, Medová M, Zimmer Y, Aebersold DM. Prognostic and predictive biomarkers in head and neck squamous cell carcinoma treated with radiotherapy – A systematic review. Biomedicines. 2022 Dec 19;10(12):3288. doi: 10.3390/biomedicines10123288.

2023

• Zabini A, Zimmer Y, Medová M. Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteins. Trends Cell Biol. 2023 Jan;33(1):5-8. doi: 10.1016/j.tcb.2022.08.002. Epub 2022 Sep 1.
• Dennstädt F, Medová M, Putora PM, Glatzer M. Parameters oft he Lyman model for calculation of normal-tissue complication probability: A systematic literature review. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):696-706. doi: 10.1016/j.ijrobp.2022.08.039. Epub 2022 Aug 24.
• Hovhannisyan L, Riether C, Aebersold DM, Medová M, Zimmer Y. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks. Mol Cancer. 2023 May 12;22(1):82. doi: 10.1186/s12943-023-01775-1.
• Koch JP, Roth SM, Quintin A, Gavini J, Orlando E, Riedo R, Pozzato C, Hayrapetyan L, Aebersold R, Stroka DM, Aebersold DM, Medo M, Zimmer Y, Medová M. A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage response. Oncogene. 2023 Jun;42(26):2113-2125. doi: 10.1038/s41388-023-02714-6. Epub 2023 May 15.
• Esposito R, Lanzós A, Uroda T, Ramnarayanan S, Büchi I, Polidori T, Guillen-Ramirez H, Mihaljevic A, Merlin BM, Mela L, Zoni E, Hovhannisyan L, McCluggage F, Medo M, Basile G, Meise DF, Zwyssig S, Wenger C, Schwarz K, Vancura A, Bosch-Guiteras N, Andrades Á, Tham AM, Roemmele M, Ochsenbein AF, Riether C, Kruithof-de Julio M, Zimmer Y, Medová M, Stroka D, Fox A, Johnson R. Tumour mutations in long noncoding RNAs enhance cell fitness. Nat Commun. 2023 Jun 8;14(1):3342. doi: 10.1038/s41467-023-39160-7.